Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment
Overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) has improved in the era of multi-line sequential therapy. The application of antiviral therapy and its impact on survival for patients with HBV-related HCC needs to be reassessed. The aim of this study was to evaluate the...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/14/11/2355 |
| _version_ | 1797466303949176832 |
|---|---|
| author | I-Cheng Lee Pei-Chang Lee Yee Chao Chen-Ta Chi Chi-Jung Wu Yi-Ping Hung Chien-Wei Su Ming-Chih Hou Yi-Hsiang Huang |
| author_facet | I-Cheng Lee Pei-Chang Lee Yee Chao Chen-Ta Chi Chi-Jung Wu Yi-Ping Hung Chien-Wei Su Ming-Chih Hou Yi-Hsiang Huang |
| author_sort | I-Cheng Lee |
| collection | DOAJ |
| description | Overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) has improved in the era of multi-line sequential therapy. The application of antiviral therapy and its impact on survival for patients with HBV-related HCC needs to be reassessed. The aim of this study was to evaluate the application and impact of antiviral therapy on survival for patients with HBV-related HCC receiving tyrosine kinase inhibitor (TKI) therapy. Patients with advanced HBV-related HCC treated with sorafenib or lenvatinib as first-line therapy with (<i>n</i> = 377) and without (<i>n</i> = 182) nucleos(t)ide analogue (NUC) therapy were retrospectively enrolled. Prognostic factors of OS were evaluated. Secular trends in the increased application of NUC therapy and improved survival were observed in the last decade. The HBV reactivation rate in patients without NUC therapy was 6.6%. By multivariate analysis, baseline low HBV viral load, achieving undetectable HBV DNA after TKI therapy, and ability to receive second-line therapy were found to be independent predictors of OS. In subgroup patients with NUC therapy, starting NUC before TKI was associated with a better OS. In conclusion, the application of antiviral therapy for patients with HBV-related HCC receiving TKI therapy has increased over time. Achieving complete virological suppression may contribute to a better OS in patients with advanced HBV-related HCC. |
| first_indexed | 2024-03-09T18:33:57Z |
| format | Article |
| id | doaj.art-28b86e1d2e5c4c7680d3cf559f8cc26c |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-09T18:33:57Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-28b86e1d2e5c4c7680d3cf559f8cc26c2023-11-24T07:15:52ZengMDPI AGViruses1999-49152022-10-011411235510.3390/v14112355Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib TreatmentI-Cheng Lee0Pei-Chang Lee1Yee Chao2Chen-Ta Chi3Chi-Jung Wu4Yi-Ping Hung5Chien-Wei Su6Ming-Chih Hou7Yi-Hsiang Huang8Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei 112, TaiwanDivision of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei 112, TaiwanSchool of Medicine, National Yang Ming Chiao Tung University, Taipei 112, TaiwanDivision of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei 112, TaiwanDivision of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei 112, TaiwanSchool of Medicine, National Yang Ming Chiao Tung University, Taipei 112, TaiwanDivision of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei 112, TaiwanDivision of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei 112, TaiwanDivision of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei 112, TaiwanOverall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) has improved in the era of multi-line sequential therapy. The application of antiviral therapy and its impact on survival for patients with HBV-related HCC needs to be reassessed. The aim of this study was to evaluate the application and impact of antiviral therapy on survival for patients with HBV-related HCC receiving tyrosine kinase inhibitor (TKI) therapy. Patients with advanced HBV-related HCC treated with sorafenib or lenvatinib as first-line therapy with (<i>n</i> = 377) and without (<i>n</i> = 182) nucleos(t)ide analogue (NUC) therapy were retrospectively enrolled. Prognostic factors of OS were evaluated. Secular trends in the increased application of NUC therapy and improved survival were observed in the last decade. The HBV reactivation rate in patients without NUC therapy was 6.6%. By multivariate analysis, baseline low HBV viral load, achieving undetectable HBV DNA after TKI therapy, and ability to receive second-line therapy were found to be independent predictors of OS. In subgroup patients with NUC therapy, starting NUC before TKI was associated with a better OS. In conclusion, the application of antiviral therapy for patients with HBV-related HCC receiving TKI therapy has increased over time. Achieving complete virological suppression may contribute to a better OS in patients with advanced HBV-related HCC.https://www.mdpi.com/1999-4915/14/11/2355hepatitis B virushepatocellular carcinomatyrosine kinase inhibitorantiviral therapysorafeniblenvatinib |
| spellingShingle | I-Cheng Lee Pei-Chang Lee Yee Chao Chen-Ta Chi Chi-Jung Wu Yi-Ping Hung Chien-Wei Su Ming-Chih Hou Yi-Hsiang Huang Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment Viruses hepatitis B virus hepatocellular carcinoma tyrosine kinase inhibitor antiviral therapy sorafenib lenvatinib |
| title | Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment |
| title_full | Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment |
| title_fullStr | Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment |
| title_full_unstemmed | Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment |
| title_short | Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment |
| title_sort | application and impact of antiviral therapy for patients with hbv related hepatocellular carcinoma receiving sorafenib and lenvatinib treatment |
| topic | hepatitis B virus hepatocellular carcinoma tyrosine kinase inhibitor antiviral therapy sorafenib lenvatinib |
| url | https://www.mdpi.com/1999-4915/14/11/2355 |
| work_keys_str_mv | AT ichenglee applicationandimpactofantiviraltherapyforpatientswithhbvrelatedhepatocellularcarcinomareceivingsorafenibandlenvatinibtreatment AT peichanglee applicationandimpactofantiviraltherapyforpatientswithhbvrelatedhepatocellularcarcinomareceivingsorafenibandlenvatinibtreatment AT yeechao applicationandimpactofantiviraltherapyforpatientswithhbvrelatedhepatocellularcarcinomareceivingsorafenibandlenvatinibtreatment AT chentachi applicationandimpactofantiviraltherapyforpatientswithhbvrelatedhepatocellularcarcinomareceivingsorafenibandlenvatinibtreatment AT chijungwu applicationandimpactofantiviraltherapyforpatientswithhbvrelatedhepatocellularcarcinomareceivingsorafenibandlenvatinibtreatment AT yipinghung applicationandimpactofantiviraltherapyforpatientswithhbvrelatedhepatocellularcarcinomareceivingsorafenibandlenvatinibtreatment AT chienweisu applicationandimpactofantiviraltherapyforpatientswithhbvrelatedhepatocellularcarcinomareceivingsorafenibandlenvatinibtreatment AT mingchihhou applicationandimpactofantiviraltherapyforpatientswithhbvrelatedhepatocellularcarcinomareceivingsorafenibandlenvatinibtreatment AT yihsianghuang applicationandimpactofantiviraltherapyforpatientswithhbvrelatedhepatocellularcarcinomareceivingsorafenibandlenvatinibtreatment |